FDA Panel Rejects Use of BPH Drugs for Prostate Cancer Prevention - Renal and Urology News
Links shared publicly online about this topic.
- 682total visits
FDA Panel Rejects Use of BPH Drugs for Prostate Cancer Prevention - Renal and Urology News
An FDA advisory panel has voted against expanding the labeling of dutasteride (Avodart, GlaxoSmithKline) and finasteride (Proscar, Merck) so that these drugs--"which are indicated for the treatment of benign prostatic hyperplasia (BPH)--"could be marketed for the prevention of prostate cancer (PCa) in men at risk for the disease.
View full resource at renalandurologynews.com
Tags: Cancer, Prostate Cancer, Prostate, Drug, Men's Health, FDA, Enlarged Prostate
Most Recently Shared on December 3, 2010 at 2:57 pm By:
FDA Panel Rejects Use of BPH Drugs for Prostate Cancer Prevention http://bit.ly/h7iraU
Also Shared By:
Advertisement
Renal Urology News
@renalandurology
FDA Panel Rejects Use of BPH Drugs for Prostate Cancer Prevention: An FDA advisory panel has voted against expan... http://bit.ly/dNQ4zo
1 year ago...